Oragenics Activates All Australian Phase IIa Trial Sites for Concussion Drug ONP-002

Oragenics Inc. (NYSE American: OGEN) announced that all three sites in its Australian Phase IIa clinical trial of ONP-002 for mild traumatic brain injury (concussion) are now active and enrolling participants, following the activation of Royal Adelaide Hospital. The company reported that no serious adverse events have been observed in dosed participants to date and continues to target a Phase IIa data readout in the fourth quarter of 2026.

The news marks a significant step forward for the clinical-stage biotechnology company, which is developing brain-targeted therapeutics through proprietary intranasal delivery technology. ONP-002 is being investigated as a potential first-in-class treatment for concussion and mild traumatic brain injury, a condition that affects millions globally each year and currently lacks FDA-approved therapies.

In parallel with the Australian trial progress, Oragenics submitted a Type B meeting request to the U.S. Food and Drug Administration on June 26 to obtain guidance on its planned U.S. clinical development program for ONP-002. The company stated that this meeting supports its goal of submitting an Investigational New Drug application in the fourth quarter of 2026. The Type B meeting is a formal mechanism for the FDA to provide advice on specific development issues, which could streamline the path to U.S. trials.

The implications of these developments are twofold. First, the activation of all Australian sites and the absence of serious adverse events suggest that the trial is on track, potentially providing important safety and efficacy data by late 2026. Second, the engagement with the FDA indicates Oragenics is proactively aligning its U.S. strategy with regulatory expectations, which could accelerate the timeline for bringing ONP-002 to market in the United States. For the millions of concussion patients, a novel treatment could address a significant unmet medical need.

Oragenics’ intranasal delivery platform has potential applications across multiple neurological conditions, including Parkinson’s disease, Alzheimer’s disease, PTSD, and anxiety disorders. While the company is currently focused on ONP-002 for concussion, the platform technology could broaden its pipeline in the future.

For more information about Oragenics and its progress, visit the company’s website at oragenics.com. The latest news and updates relating to OGEN are available in the company’s newsroom at https://ibn.fm/OGEN.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Oragenics Activates All Australian Phase IIa Trial Sites for Concussion Drug ONP-002.

The post Oragenics Activates All Australian Phase IIa Trial Sites for Concussion Drug ONP-002 appeared first on citybuzz.